The startup develops bio-printed three-dimensional human bone tissue using pneumatic extrusion technology, creating a native-like micro-architecture for in-vitro efficacy and toxicity assays. This technology enables pharmaceutical companies to conduct drug testing with artificial human tissues, bridging the gap between pre-clinical and clinical phases of drug development.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development relies heavily on animal models and traditional 2D cell cultures, which often fail to accurately predict human responses, leading to costly failures in clinical trials. The lack of human-relevant in-vitro models hinders the ability to effectively assess drug efficacy and toxicity in a pre-clinical setting.
Solution
Printivo develops 3D-bioprinted human bone tissue for in-vitro drug efficacy and toxicity assays, offering a more predictive alternative to traditional methods. Using pneumatic extrusion technology, Printivo creates bone tissue with a native-like microarchitecture, mimicking the complexity of human tissue. Their bioprinted bone grafts provide pharmaceutical companies with a human-relevant model for drug testing in pre-clinical trials, bridging the gap between pre-clinical and clinical phases. Printivo's technology enables the creation of bone tissue models that represent the dimensional complexity of native human tissue and cell-to-cell interactions, providing more accurate data on how new molecules affect cells and predict their toxicity.
Target Audience
Printivo's primary customers are pharmaceutical companies seeking more accurate and sophisticated data for drug testing in pre-clinical trials.
Features
- 3D-bioprinting using proprietary pneumatic extrusion technology (EVE bioprinter)
- ADAM: multipotent bioink formulas based on collagen and synthetic/natural polymers to sustain cellular life
- Tissue engineering to optimize the microarchitecture of tissue constructs, enhancing cell vitality and cellular interactions
- Use of stem cells and differentiated cell lines to mimic native human tissues
- Creation of bone tissue models that represent the dimensional complexity of native human tissue and cell-to-cell interactions